Furthermore, Sakaue et al. found that increased levels of sialic acids of CD133 glycoprotein from the pancreatic cancer patient’s ascites-derived exosomes, and indicated that highly glycosylated CD133 could be a potential biomarker for advanced pancreatic cancer [31]. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.